Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Novartis
Deloitte
Julphar
Harvard Business School
Queensland Health
Daiichi Sankyo
Johnson and Johnson
Chinese Patent Office
Healthtrust

Generated: January 19, 2018

DrugPatentWatch Database Preview

Covis Pharma Bv Company Profile

« Back to Dashboard

What is the competitive landscape for COVIS PHARMA BV, and when can generic versions of COVIS PHARMA BV drugs launch?

COVIS PHARMA BV has seven approved drugs.

There are four US patents protecting COVIS PHARMA BV drugs.

There are fifty-four patent family members on COVIS PHARMA BV drugs in twenty countries and five supplementary protection certificates in two countries.

Summary for Covis Pharma Bv
International Patents:54
US Patents:4
Tradenames:8
Ingredients:6
NDAs:7

Drugs and US Patents for Covis Pharma Bv

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Covis Pharma Bv SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-006 Jan 2, 2008 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Covis Pharma Bv BETAPACE AF sotalol hydrochloride TABLET;ORAL 021151-002 Feb 22, 2000 AB2 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Covis Pharma Bv BETAPACE sotalol hydrochloride TABLET;ORAL 019865-001 Oct 30, 1992 AB1 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-003 Jun 26, 2002 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Covis Pharma Bv LANOXIN digoxin INJECTABLE;INJECTION 009330-002 Approved Prior to Jan 1, 1982 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-001 Jun 26, 2002 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Covis Pharma Bv BETAPACE AF sotalol hydrochloride TABLET;ORAL 021151-007 Apr 2, 2003 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Covis Pharma Bv BETAPACE AF sotalol hydrochloride TABLET;ORAL 021151-006 Apr 2, 2003 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Covis Pharma Bv BETAPACE AF sotalol hydrochloride TABLET;ORAL 021151-001 Feb 22, 2000 AB2 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-003 Jun 26, 2002 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Covis Pharma Bv

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Covis Pharma Bv SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-007 Jan 2, 2008 ➤ Subscribe ➤ Subscribe
Covis Pharma Bv PRILOSEC omeprazole magnesium FOR SUSPENSION, DELAYED RELEASE;ORAL 022056-002 Mar 20, 2008 ➤ Subscribe ➤ Subscribe
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-003 Jun 26, 2002 ➤ Subscribe ➤ Subscribe
Covis Pharma Bv PRILOSEC omeprazole magnesium FOR SUSPENSION, DELAYED RELEASE;ORAL 022056-001 Mar 20, 2008 ➤ Subscribe ➤ Subscribe
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-003 Jun 26, 2002 ➤ Subscribe ➤ Subscribe
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-001 Jun 26, 2002 ➤ Subscribe ➤ Subscribe
Covis Pharma Bv SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-004 Feb 2, 1995 ➤ Subscribe ➤ Subscribe
Covis Pharma Bv RILUTEK riluzole TABLET;ORAL 020599-001 Dec 12, 1995 ➤ Subscribe ➤ Subscribe
Covis Pharma Bv SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-004 Feb 2, 1995 ➤ Subscribe ➤ Subscribe
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-002 Jun 26, 2002 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for COVIS PHARMA BV drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 8.5 mg and 17 mg ➤ Subscribe 3/2/2009
➤ Subscribe Extended-release Tablets 25.5 mg and 34 mg ➤ Subscribe 11/28/2008
➤ Subscribe Extended-release Tablets 20 mg and 30 mg ➤ Subscribe 11/7/2007
➤ Subscribe Extended-release Tablets 40 mg ➤ Subscribe 6/11/2007

Non-Orange Book US Patents for Covis Pharma Bv

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,679,534 HMG-CoA reductase inhibitor extended release formulation ➤ Subscribe
6,440,387 Methods for determining risk of Alzheimer's disease ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Covis Pharma Bv Drugs

Supplementary Protection Certificates for Covis Pharma Bv Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB11/013 United Kingdom ➤ Subscribe PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
11/016 Ireland ➤ Subscribe PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
12/048 Ireland ➤ Subscribe PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
C/GB01/006 United Kingdom ➤ Subscribe PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
C/GB11/015 United Kingdom ➤ Subscribe PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Baxter
US Department of Justice
McKesson
Cipla
US Army
QuintilesIMS
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot